HIGHTIDE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.24 HKD | -3.41% |
|
-7.69% | -51.85% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 2.98B 23.24B |
|---|---|---|---|---|---|
| Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
| Net Debt 2024 * | 28.02M 219M | Net Debt 2025 * | 400M 3.12B | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-10.2
x | P/E ratio 2025 * |
-
| Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 11.99% |
More Fundamentals
* Assessed data
More news
| 1 day | -3.41% | ||
| 1 week | -7.69% | ||
| Current month | +28.40% | ||
| 1 month | +25.55% | ||
| 3 months | -48.09% | ||
| Current year | -51.85% |
1 week
6.18
7.30
1 month
4.647.98
Current year
4.0013.18
1 year
4.0013.18
3 years
4.0013.18
5 years
4.0013.18
10 years
4.0013.18
| Managers | Title | Age | Since |
|---|---|---|---|
Li Ping Liu
CEO | Chief Executive Officer | 55 | 10-12-31 |
Koon Yin Sim
DFI | Director of Finance/CFO | 55 | 22-11-30 |
Cathryn Bennett
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bo Tan
BRD | Director/Board Member | 51 | - |
Xun Zhu
BRD | Director/Board Member | 66 | 20-11-29 |
Jin Li
BRD | Director/Board Member | 59 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-20 | 6.24 | -3.41% | 2 116 000 |
| 24-05-17 | 6.46 | -6.38% | 1,225,500 |
| 24-05-16 | 6.9 | -0.72% | 6,234,500 |
| 24-05-14 | 6.95 | -0.86% | 950,500 |
| 24-05-13 | 7.01 | +3.70% | 2,090,000 |
Delayed Quote Hong Kong S.E., May 20, 2024 at 04:08 am EDT
More quotes
HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The Company has developed a product pipeline of multiple product candidates in-house, covering many indications in metabolic and digestive diseases among which, some are at clinical-stage. The Companyâs core product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases. The Company conducts operations in the United States, Mainland China, Hong Kong and Australia.
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
5.789
CNY
Average target price
15.62
CNY
Spread / Average Target
+169.83%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -51.85% | 426M | |
| +9.58% | 115B | |
| +12.41% | 106B | |
| -2.59% | 21.96B | |
| -12.38% | 21.87B | |
| -5.29% | 19.21B | |
| -3.35% | 18.08B | |
| -38.57% | 17.71B | |
| +7.51% | 14.32B | |
| +35.67% | 12.42B |
- Stock Market
- Equities
- 2511 Stock
